Curetis and Axonlab Distribution Agreement
Curetis and Axonlab Sign Multi-Market European Distribution Agreement
– Axonlab to become exclusive distributor for all Unyvero products in selected Central and Eastern European countries
Amsterdam, the Netherlands, Holzgerlingen, Germany, and Baden, Switzerland, June 06, 2016 — Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, and Axon Lab AG, a service company focusing on medical diagnostics, life science and software solutions for the healthcare sector, todayannounced the signing of an exclusive, three-year distribution agreement for Curetis’ Unyvero products in Central and Eastern European countries, including Austria, the Czech Republic, Slovakia, Slovenia and Croatia. The agreement also includes contractual minimum purchase commitments by Axonlab.
Through the partnership, Curetis expands its distribution network by four additional countries and transfers the commercialization responsibilities for one of its former direct selling territories (Austria) to Axonlab. The agreement is part of Curetis’ expanded commercial effort in Western Europe and allows the companies to leverage Curetis’ existing installed base in Austria, with Axonlab acquiring multiple commercially installed Unyvero Systems for cash up-front.
Axonlab will deploy a core team of several dedicated molecular diagnostics commercial representatives covering these markets. This deployment structure will ensure optimal resource allocation for Curetis in the region.
Axonlab has dedicated microbiology and molecular diagnostics franchises and direct offices in each of the countries covered under the agreement, and it is well positioned to accelerate the commercial launch of Unyvero in the CEE markets.
Curetis will continue its direct sales programs in its home market of Germany, as well as in Switzerland, the UK, France and the Benelux region.
“We are excited to partner with Curetis for the commercial distribution of the Unyvero Platform with all of its current and future Application Cartridges in several of our core markets in Europe,” said Guido Mueller, General Manager Austria of Axonlab. “We believe that Unyvero offers unique and differentiated syndromic panels to our customers in hospitals and microbiology laboratories. This collaboration is expected to be another driver for our future growth here at Axonlab in the years ahead.”
Dr. Achim Plum, Chief Commercial Officer of Curetis N.V., added, “This strategic commercial distribution agreement for multiple markets in Central and Eastern Europe makes perfect business sense for Curetis. We expect that the Axonlab partnership will allow us to accelerate the commercial roll-out of Unyvero products in smaller markets, such as Austria, while adding several new markets to our distribution portfolio. Moreover, the agreement allows us to focus our direct commercial efforts on the largest Western European markets, such as the UK, France, Benelux and Germany as well as Switzerland, to drive our growth. We currently have a presence in more than thirty countries, either directly or through our ten distribution partners. We plan to continue expanding this worldwide network through the addition of new commercial partners.”
CAUTION – Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.
Axonlab is an independent corporation involved in distribution, service, software, and production activities for customers in medical / diagnostic labs and the life sciences. With its 25 years of experience, Axonlab stands for the highest degree of excellence in service and system oriented solutions. The company has more than 240 employees in Switzerland, Germany, Austria, Belgium, Czech Republic, Slovenia, and Croatia. Axonlab sees itself as a sustainable company and an active and reliable partner for hospitals, doctors, private laboratories, and public and private research.
For more information, visit www.axonlab.com
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis’ actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
According to §§ 190 ff. German Reorganization Act (UmwG) and by way of enrolment in the commercial register at district court Stuttgart on March 15, 2016 Curetis plc (AG) changed its legal form into Curetis Ltd. (GmbH).
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
firstname.lastname@example.org or email@example.com
www.curetis.com – www.unyvero.com
International Media & Investor Inquiries
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Tel. +1 646 536 7012
Elena Christina Billig
Tel: +49 (0) 7031 9231961
Mobile: +49 (0) 1786352386
Fax: +49 (0) 7031 49195-19
Geschäftsführer: Oliver Schacht, PhD, Andreas Boos, Johannes Bacher, Dr. Achim Plum, Heiko Schorr
Amtsgericht Stuttgart HRB 756134